Navigation Links
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Date:1/30/2008

SOMERSET, N.J., Jan. 30 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that 311 evaluable events (patient deaths) have occurred in the Phase IIIb clinical trial of its lead compound, ONCONASE, for the treatment of patients with unresectable malignant mesothelioma. Enrollment in the ONCONASE Phase IIIb clinical trial was closed on Sept. 30, 2007. A total of 428 patients were enrolled in the trial.

In accordance with the statistical plan for the study, the company must wait until 316 evaluable events have occurred to conduct the formal statistical analysis required to complete the final sections of the ONCONASE rolling New Drug Application (NDA). To be considered evaluable, patients must meet all of the eligibility requirements for the study and receive at least one dose of study drug.

About ONCONASE(R)

ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alface
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
7. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
8. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
9. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
10. BioCryst Updates Peramivir Clinical Development Plan
11. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... NEW YORK , June 17, 2013  A little ... has come under scrutiny by the U.S. Supreme Court – ... on the issue could not have come at a better ... issues that result from the Rx industry tactic are all ... AARP survey of 50+ New Yorkers, state residents are in ...
(Date:6/17/2013)... 2013 Franciscan St. Francis Health Cancer Center ... Indiana to use a new drug ... It,s called Xofigo ®, a radiopharmaceutical used in patients ... It recently was approved for use by the U.S. Food ... advanced stages it may become castration-resistant, which has become resistant ...
(Date:6/17/2013)... WASHINGTON , June 17, 2013  The ... the most comprehensive report on the effectiveness of ... restrictions on these FDA-approved drugs by many state ... more Americans than drunk driving car crashes, an ... and use of heroin. Yet, safe and effective ...
Breaking Medicine Technology:Supreme Court Ruling on Rx Industry's Pay-to-Delay-Generics Good News for NY Consumers 2Supreme Court Ruling on Rx Industry's Pay-to-Delay-Generics Good News for NY Consumers 3New drug proving effective in attacking advanced prostate cancer 2Effective Rx thwarted for deadly opiate epidemic 2
... Into a Collaborative Research Agreement With The University of Texas M. ... Breast ... Cancer, VEDBAEK, ... analysis products, today,announces that it has signed a collaborative research agreement with ...
... Approved in 40 Countries ... ... Massachusetts, May 27, Shire Limited (LSE: SHP, NASDAQ: SHPGY), the,global ... therapy for the treatment of,Hunter syndrome, has been approved by ...
Cached Medicine Technology:Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center 2Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center 3Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil 2Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil 3Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil 4Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil 5
(Date:6/17/2013)... June 17, 2013 "Do you think you ... texting, emailing or using your phone even with a hands ... it is just as dangerous as not using a hands ... of you using Facebook, texting, emailing etc." , ... alters their reflexes that distract the brain, according to a ...
(Date:6/17/2013)... (PRWEB) June 17, 2013 Bust’DD (pronounced ‘busted’), ... stylish and well-fitting to women with large busts, will soon ... by two women who understand the problem of ill-fitting bras ... busty women. Their goal is to raise at least $25,000 ... of offering their bras on a wide scale. , In ...
(Date:6/17/2013)... June 17, 2013 The personal ... LLP are pleased to announce that firm Partners ... L. Scher ( http://www.blockotoole.com/Attorneys/David-L-Scher.shtml ) will be appearing ... FM) this Sunday, June 23, 2013 at 7a.m. ... guests on Kevin Burke's "Get Active" show, which ...
(Date:6/17/2013)... Park City, Utah (PRWEB) June 17, 2013 ... information on stand-alone HRAs for small businesses ... alternatives to traditional employer sponsored health benefits, is ... health reimbursement arrangements . , According to ... called Health Reimbursement Accounts or HRAs, offer small ...
(Date:6/17/2013)... According to a June 11, 2013 ABC ... and more information surfaces about the negative effects of ... part of one’s skin care routine, as the ... goo.gl/qTKZQ). , “I agree with the article's suggestions for ... Medical Director of Epione Beverly Hills. “Apply a minimum of ...
Breaking Medicine News(10 mins):Health News:Dr. Bonnie Weil Warns Hands Free is Not a Life Saver, It Can Be Just as Much of a Distraction 2Health News:Arizona Startup Bust’DD Looking to Start a BRAvolution 2Health News:Arizona Startup Bust’DD Looking to Start a BRAvolution 3Health News:Injury Attorneys Block O'Toole & Murphy, LLP to Appear on Z100 Radio Show This Sunday to Discuss Their Support of St. Jude Children's Research Hospital 2Health News:Zane Benefits Publishes New Information on Stand-Alone HRAs for Small Businesses 2Health News:Skin Care – Answers to Your Sunscreen Questions 2
... connectivity for ... Cardiac Rehabilitation, BOTHELL, ... a global leader in advanced cardiac monitoring,and defibrillation products, announced ... now has seamless connectivity with LUMEDX,CardioWellness(TM) data management software. ...
... as Evelyn Bickley wins CBay,s ,Keys to Medical ... Records ... leading provider,of transcription and healthcare BPO services, today announced the ... year,s AHIMA,Convention and Exhibit in Philadelphia. (Photo: http://www.newscom.com/cgi-bin/prnh/20071017/NEW009 ...
... Inc.,(Nasdaq: ATRC ), a medical device company ... that results reporting on the Company,s,proprietary minimally invasive ... (AF), were published in the Journal of,Cardiovascular Electrophysiology ... from the Oregon Heart and Vascular,Institute. The ...
... WASHINGTON, Oct. 16 Speaker Nancy Pelosi,Senate Majority Leader ... Paul Simon, Families USA, Easter Seals, and other advocates ... Congress to override the,President,s veto of the Children,s Health ... Ron Pollack, to Families USA, to Easter Seals, and ...
... Stock Exchange Symbol: CYT, MONTREAL, Oct. ... leader in cardiac arrhythmia products to treat ... Inc. a patent,infringement lawsuit in the United ... CryoCor makes and sells cryosurgical consoles, ...
... 1st issue of G&D, Dr. Michael Cleary (Stanford University ... as a critical player in the establishment of leukemia ... Mixed lineage leukemia (MLL) is a distinctive type of ... leukemia (ALL) by the presence of a break and ...
Cached Medicine News:Health News:Cardiac Science Announces Data Connectivity with LUMEDX 2Health News:Cardiac Science Announces Data Connectivity with LUMEDX 3Health News:Cardiac Science Announces Data Connectivity with LUMEDX 4Health News:CBaySystems Gives Away 2008 Honda Civic at AHIMA 2007 2Health News:Published Results Using AtriCure Minimally Invasive Products 2Health News:Published Results Using AtriCure Minimally Invasive Products 3Health News:Pelosi: In 48 Hours, Congress Must Choose Between Meeting the Needs of America's Children or Not 2
... Engine is a core software ... System, which enables location-based applications ... Core capabilities of the AeroScout ... positioning, management of AeroScout hardware ...
... Bracelet-ID™ provides a solution for instantaneously ... elopement or unauthorized movement of patients ... a key concern. Certain patients, such ... victims, patients with highly communicable diseases, ...
... Kisses tag is part of the ... Hugs system. The Kisses tag is ... it has been bonded with the ... he two tags remain electronically bonded ...
... small radio transmitter combines state-of-the-art microprocessor ... The tag incorporates a tamper mechanism ... the tag is attached to the ... Heartbeat® signal every 10 seconds to ...
Medicine Products: